Endogenous growth inhibition of angiogenesis in brain tumors

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 469-479

  Kirsch, Matthias ^a,b   Allende, Rafael ^b   Black, Peter ^b   Schackert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Brain tumor; Dormancy; Endogenous inhibition; Glioma; Metastasis

Indexed keywords

MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CARCINOGENESIS; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; GLIOMA CELL; GROWTH INHIBITION; HEMISPHERE; IMPLANTATION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS;

EID: 36148957476     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9076-9     Document Type: Article

References (69)

1. Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1(2), 149-153.
2. Murray, C. (1995). Tumor dormancy: not so sleepy after all. Nature Medicine, 1(2), 117-118.
3. Fujii, Y., Fukui, I., Kihara, K., Tsujii, T., Kageyama, Y., & Oshima, H. (1999). Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer. European Urology, 36(4), 309-313.
4. Karrison, T. G., Ferguson, D. J., & Meier, P. (1999). Dormancy of mammary carcinoma after mastectomy [see comments]. Journal of the National Cancer Institute, 91(1), 80-85.
5. Meltzer, A. (1990). Dormancy and breast cancer. Journal of Surgical Oncology, 43(3), 181-188.
6. Stewart, T. H., Hollinshead, A. C., & Raman, S. (1991). Tumour dormancy: initiation, maintenance and termination in animals and humans [see comments]. Canadian Journal of Surgery, 34(4), 321-325.
7. Crowley, N. J., & Seigler, H. F. (1992). Relationship between disease-free interval and survival in patients with recurrent melanoma. Archives of Surgery, 127(11), 1303-1308.
8. Demicheli, R., Terenziani, M., Valagussa, P., Moliterni, A., Zambetti, M., & Bonadonna, G. (1994). Local recurrences following mastectomy: support for the concept of tumor dormancy [see comments]. Journal of the National Cancer Institute, 86(1), 45-48.
9. Demicheli, R., Abbattista, A., Miceli, R., Valagussa, P., & Bonadonna, G. (1996). Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Research and Treatment, 41(2), 177-185.
10. Spratt, J. S., Meyer, J. S., & Spratt, J. A. (1996). Rates of growth of human neoplasms: Part II. Journal of Surgical Oncology, 61(1), 68-83.
11. Spratt, J. S., Meyer, J. S., & Spratt, J. A. (1995). Rates of growth of human solid neoplasms: Part I. Journal of Surgical Oncology, 60(2), 137-146.
12. Thybusch-Bernhardt, A., Klomp, H. J., Maas, T., Kremer, B., & Juhl, H. (1999). Immunocytological detection of isolated tumour cells in the bone marrow of malignant melanoma patients: a new method for the detection of minimal residual disease. European Journal of Surgical Oncology, 25(5), 498-502.
13. Braun, S., & Pantel, K. (1999). Micrometastatic bone marrow involvement: detection and prognostic significance. Medical Oncology, 16(3), 154-165.
14. Roder, J. D., Thorban, S., Pantel, K., & Siewert, J. R. (1999). Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World Journal of Surgery, 23(9), 888-891.
15. Hirsch-Ginsberg, C. (1998). Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies. Annual Review of Medicine, 49, 111-122.
16. Thorban, S., Roder, J. D., Nekarda, H., Funk, A., Pantel, K., & Siewert, J. R. (1996). Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: detection and prognostic significance. World Journal of Surgery, 20(5), 567-572.
17. Hsu, E., Keene, D., Ventureyra, E., Matzinger, M. A., Jimenez, C., Wang, H. S., et al. (1998). Bone marrow metastasis in astrocytic gliomata. Journal of Neuro-oncology, 37(3), 285-293.
18. LoRusso, P. M., Tapazoglou, E., Zarbo, R. J., Cullis, P. A., Austin, D., & Al Sarraf, M. (1988). Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature. Journal of Neuro-oncology, 6(1), 53-59.
19. Newman, H. F., Howard, G. C., & Reid, P. M. (1985). Metastatic oligodendroglioma presenting as a leukoerythroblastic anaemia. European Journal of Surgical Oncology, 11(3), 287-288.
20. Terheggen, H. G., & Muller, W. (1977). Extracerebrospinal metastases in glioblastoma. Case report and review of the literature. European Journal of Pediatrics, 124(2), 155-164.
21. Yung, W. K., Tepper, S. J., & Young, D. F. (1983). Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase- antiperoxidase staining for glial fibrillary acidic protein. Annals of Neurology, 14(5), 581-585.
22. Frank, S., Muller, J., Bonk, C., Haroske, G., Schackert, H. K., & Schackert, G. (1998). Transmission of glioblastoma multiforme through liver transplantation. Lancet, 352(9121), 31.
23. Gaspar, L. E., Fisher, B. J., Macdonald, D. R., LeBer, D. V., Halperin, E. C., Schold, S. C., Jr., et al. (1992). Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. International Journal of Radiation Oncology, Biology, Physics, 24(1), 55-57.
24. Burger, P. C., Dubois, P. J., Schold, S. C., Jr., Smith, K. R., Jr., Odom, G. L., Crafts, D. C., et al. (1983). Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. Journal of Neurosurgery, 58(2), 159-169.
25. Russell, D. S., & Rubinstein, L. J. (1989). Pathology of tumors of the nervous system. Baltimore: Williams and Wilkins.
26. Schlegel, U., Weller, M., & Westphal, M. (2003). Neuroonkologie. ed 2, Thieme. New York: Stuttgart.
27. Burger, P. C., & Vollmer, R. T. (1980). Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer, 46(5), 1179-1186.
28. Burger, P. C., Heinz, E. R., Shibata, T., & Kleihues, P. (1988). Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. Journal of Neurosurgery, 68(5), 698-704.
29. Chicoine, M. R., & Silbergeld, D. L. (1995). Invading C6 glioma cells maintaining tumorigenicity. Journal of Neurosurgery, 83(4), 665-671.
30. Bernstein, J. J., Goldberg, W. J., & Laws, E. R., Jr. (1989). Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. Journal of Neuroscience Research, 22(2), 134-143.
31. Goldberg, W. J., Laws, E. R., Jr., & Bernstein, J. J. (1991). Individual C6 glioma cells migrate in adult rat brain after neural homografting. International Journal of Developmental Neuroscience, 9(4), 427-437.
32. Laws, E. R., Jr., Goldberg, W. J., & Bernstein, J. J. (1993). Migration of human malignant astrocytoma cells in the mammalian brain: Scherer revisited. International Journal of Developmental Neuroscience, 11(5), 691-697.
33. Chicoine, M. R., & Silbergeld, D. L. (1995). Assessment of brain tumor cell motility in vivo and in vitro. Journal of Neurosurgery, 82(4), 615-622.
34. Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine, 324(1), 1-8.
35. Leon, S. P., Folkerth, R. D., & Black, P. M. (1996). Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer, 77(2), 362-372.
36. Chirgwin, J. M., Przbyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979). Isolation of biologically active ribonucleic acid from sources enriched with ribonuclease. Biochemistry, 18, 5294-5299.
37. Carroll, R. S., Black, P. M., Zhang, J., Kirsch, M., Percec, I., Lau, N., et al. (1997). Expression and activation of epidermal growth factor receptors in meningiomas. Journal of Neurosurgery, 87(2), 315-323.
38. Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., & Black, P. M. (1998). Angiostatin suppresses malignant glioma growth in vivo. Cancer Research, 58(20), 4654-4659.
39. Araki, M., Fan, J., Haraoka, S., Moritake, T., Yoshii, Y., & Watanabe, T. (1999). Extracranial metastasis of anaplastic ganglioglioma through a ventriculoperitoneal shunt: a case report. Pathology International, 49(3), 258-263.
40. Newton, H. B., Rosenblum, M. K., & Walker, R. W. (1992). Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity. Cancer, 69(8), 2149-2153.
41. Pasquier, B., Pasquier, D., Lachard, A., N'Golet, A., Panh, M. H., & Couderc, P. (1979). Extraneural metastasis of central nervous system tumours (author's translation). Bulletin du Cancer, 66(1), 25-28.
42. Liwnicz, B. H., & Rubinstein, L. J. (1979). The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Human Pathology, 10(4), 453-467.
43. Pasquier, B., Pasquier, D., N'Golet, A., Panh, M. H., & Couderc, P. (1979). Le potentiel metastatique des tumeurs primitives du system de nerveux central. Revue Neurologique (Paris), 135(3), 263-278.
44. Diel, I. J., & Cote, R. J. (2000). Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treatment Reviews, 26(1), 53-65.
45. Ginsbourg, M., Musset, M., Misset, J. L., Genty, O., & Mathe, G. (1989). Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis-an immunocytologic study with monoclonal antibodies. Bulletin de la Societe des Sciences medicales du Grand-Duche de Luxembourg, 126(1), 51-54.
46. Riethmuller, G., & Klein, C. A. (2001). Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Seminars in Cancer Biology, 11(4), 307-311.
47. Greene, H. S. N., & Harvey, H. (1964). Metastasis from the brain. Cancer Research, 24, 1021-1027.
48. Greene, H. S. N., & Harvey, E. K. (1964). Metastasis from heterologously transplanted tumors. Cancer Research, 24, 1678-1687.
49. Russell, D. S., & Rubinstein, L. J. (1989). The growth and dissemination of central neuroepithelial tumours; pathology of tumours of the nervous system (pp. 421-448). Baltimore: Williams & Wilkins.
50. Brem, S., Brem, H., Folkman, J., Finkelstein, D., & Patz, A. (1976). Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Research, 36(8), 2807-2812.
51. Pasqualini, R., & Ruoslahti, E. (1996). Organ targeting in vivo using phage display peptide libraries. Nature, 380(6572), 364-366.
52. O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine, 2(6), 689-692.
53. Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658), 404-407.
54. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88(2), 277-285.
55. Grant, M. A., & Kalluri, R. (2005). Structural basis for the functions of endogenous angiogenesis inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 70, 399-410.
56. Hamano, Y., & Kalluri, R. (2005). Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochemical and Biophysical Research Communications, 333(2), 292-298.
57. Rege, T. A., Fears, C. Y., & Gladson, C. L. (2005). Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro-oncology, 7(2), 106-121.
58. Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., et al. (2005). Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proceedings of the National Academy of Sciences of the United States of America, 102(8), 2934-2939.
59. Folkman, J. (2004). Endogenous angiogenesis inhibitors. APMIS, 112(7-8), 496-507.
60. Cao, Y. (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. International Journal of Biochemistry & Cell Biology, 33(4), 357-369.
61. Sim, B. K., MacDonald, N. J., & Gubish, E. R. (2000). Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer and Metastasis Reviews, 19(1-2), 181-190.
62. Cao, Y. (1998). Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Progress in Molecular and Subcellular Biology, 20, 161-176.
63. Kirsch, M., Schackert, G., & Black, P. M. (2004). Metastasis and angiogenesis. Cancer Treatment and Research, 117, 285-304.
64. Beerepoot, L. V., Witteveen, E. O., Groenewegen, G., Fogler, W. E., Sim, B. K., Sidor, C., et al. (2003). Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clinical Cancer Research, 9(11), 4025-4033.
65. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542-2550.
66. Tjin Tham Sjin, R. M., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M., Folkman, J., & Javaherian, K. (2005). A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Research, 65(9), 3656-3663.
67. Yang, L., Wang, J. W., Sun, Y., Zhu, Y. Z., Liu, X. Q., Li, W. L., et al. (2006) Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 28(2), 138-141.
68. Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch, T. J., Zhu, A. X., et al. (2006). Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 24(22), 3555-3561.
69. Sun, Y., Wang, J., Liu, Y., Song, X., Zhang, Y., Li, K., et al. (2005). Results of phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology, 23(16S), 7138.